Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders.

Article Details

Citation
Copy to clipboard

Brawer MK

Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders.

Rev Urol. 2005;7 Suppl 7:S21-6.

PubMed ID
16986057 [ View in PubMed
]
Abstract

Normal and hyperplastic prostatic tissues concentrate citrate within the epithelium; however, a unique biochemical property within prostate epithelial cells renders them dependent on glycolysis, rather than the citric acid cycle, for energy production. Lonidamine, an orally administered small molecule that inhibits glycolysis by the inactivation of hexokinase, may represent a unique and novel approach to the treatment of benign prostatic hyperplasia (BPH). Results of a phase II trial of lonidamine in BPH (described elsewhere in this supplement) are encouraging. Lonidamine is already used in the treatment of several cancers in other countries. Its target-specific nature renders it a safe compound for administration; in cancer therapy, patients have been treated with 40 times the daily dose used in the BPH trial, with negligible toxicity.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
LonidamineHexokinase-1ProteinHumans
Unknown
Not AvailableDetails